Q1 table

L Heron

10/29/2021

## Full Characteristics of Q1 studies

Table :Table 1. Characteristics of studies included for Q1

| Study | Location | Total SARS-CoV-2, n | Asymptomatic SARS-CoV-2, n | Sex of asymptomatic people | Age of asymptomatic people, years, median | Follow-up methoda |
| --- | --- | --- | --- | --- | --- | --- |
| setting: Contact investigation | | | | | | |
| Bi Q, 2020 | China, Shenzhen | 87 | 17 | NR | NR | 2, 3, 4 |
| Cheng HY, 2020 | Other, Taiwan | 22 | 4 | NR | NR | 1 |
| Wu J, 2020 | China, Zhuhai | 48 | 5 | NR | NR | 1, 2, 4 |
| Hijnen D, 2020 | Germany, Munich | 11 | 1 | 0 F, 1 M | 49 | 1, 2 |
| Brandstetter S, 2020 | Germany, Regensburg | 36 | 2 | NR | NR | 2, 4 |
| Zhang W, 2020 | China, Guangzhou | 12 | 4 | NR | NR | 1, 2, 3 |
| Yousaf AR, 2020 | United States of America, Utah | 47 | 0 | NR | NR | 2, 4 |
| Luo L, 2020 | China, Guangzhou | 127 | 8 | NR | NR | 1, 4 |
| Hurst JH, 2020 | United States of America, North Carolina | 293 | 87 | NR | NR | 2 |
| Grijalva CG, 2020 | United States of America, Tennessee and Wisconsin | 102 | 34 | NR | NR | 2 |
| Shi Q, 2020 | China, Wanzhou District | 183 | 60 | NR | NR | 3 |
| Jones A, 2021 | United States of America, Vermont | 87 | 24 | NR | NR | 1, 2 |
| setting: Outbreak investigation | | | | | | |
| Danis K, 2020 | France, NR | 12 | 1 | NR | NR | 1, 2, 4 |
| Park SY, 2020 | South Korea, Seoul | 95 | 4 | NR | NR | 2, 4 |
| Arons MM, 2020 | United States of America, Seattle, WA | 47 | 3 | NR | NR | 2 |
| Schwierzeck V, 2020 | Germany, Muenster | 11 | 2 | NR | NR | 2 |
| Böhmer MM, 2020 | Germany, Bavaria | 16 | 1 | NR | NR | 1, 2 |
| Dora AV, 2020 | United States of America, Los Angeles | 16 | 6 | 0 F, 6 M | 75 IQR 72-75 | 3 |
| Graham N, 2020 | United Kingdom, London | 126 | 46 | NR | NR | 2 |
| Patel MC, 2020 | United States of America, Illinois | 35 | 13 | NR | NR | 2, 4 |
| Pavli A, 2020 | Greece, NR | 46 | 7 | NR | NR | 1, 2 |
| Njuguna H, 2020 | United States of America, Louisiana | 71 | 29 | NR | NR | 1, 2 |
| Yau K, 2020 | Canada, Toronto | 20 | 7 | NR | NR | 2, 4 |
| Lee JY, 2020 | South Korea, Daegu | 694 | 80 | NR | NR | 2 |
| Yang N, 2020 | China, Xiaoshan | 10 | 2 | 1 F, 1 M | 26 | 1, 2 |
| Pham QT, 2020 | Vietnam, NR | 208 | 89 | NR | 31 IQR 23-45 | 2 |
| Plucinski, 2020 | Japan | 66 | 14 | NR | NR | 2 |
| Kittang BR, 2020 | Norway, Bergen | 40 | 0 | NR | NR | 1, 2 |
| Corcorran MA, 2020 | United States of America, Washington | 8 | 3 | NR | NR | 2, 3 |
| Pirnay JP, 2020 | Belgium, NR | 9 | 4 | 0 F, 4 M | 34.5 IQR 24-44.5 | 1 |
| Taylor J, 2020 | United States of America, Minnesota | 99 | 9 | NR | NR | 2, 4 |
| Kennelly SP, 2020 | Ireland, NR | 710 | 193 | NR | NR | 2 |
| Romao VC, 2020 | Portugal, Lisbon | 14 | 0 | NR | NR | 3 |
| Ladhani SN, 2020 | United Kingdom, London | 105 | 46 | NR | NR | 2, 4 |
| Kasper MR, 2020 | United States of America, NR | 1,271 | 572 | NR | NR | 2, 4 |
| Redditt V, 2020 | Canada, Toronto | 24 | 3 | NR | NR | 2, 4 |
| Park JH, 2020 | South Korea, NR | 28 | 4 | NR | NR | 1, 2 |
| Harada S, 2020 | Japan, Tokyo | 24 | 8 | NR | NR | 2, 4 |
| Tian S, 2021 | China, Shandong | 24 | 7 | NR | NR | 2, 3 |
| van den Besselaar JH, 2021 | Netherlands, South Holland | 54 | 1 | NR | NR | 2, 4 |
| Taylor J, 2020 [cluster 2] | United States of America, Minnesota | 127 | 7 | NR | NR | 2, 4 |
| Kennelly SP, 2020 [cluster 2] | Ireland, NR | 395 | 97 | NR | NR | 2 |
| Ladhani SN, 2020 [cluster 2] | United Kingdom, London | 53 | 26 | NR | NR | 2, 4 |
| Harada S, 2020 [cluster 2] | Japan, Tokyo | 49 | 25 | NR | NR | 2, 4 |
| van den Besselaar JH, 2021 [cluster 2] | Netherlands, South Holland | 113 | 7 | NR | NR | 2, 4 |
| setting: Screening: community setting | | | | | | |
| Chang L, 2020 | China, Wuhan | 4 | 2 | 0 F, 2 M | 45 IQR 37-53 | 2, 3 |
| Lavezzo E, 2020 | Italy, Veneto | 73 | 29 | NR | NR | 2 |
| Hoehl S, 2020 | Germany, Germersheim | 2 | 1 | 0 F, 1 M | 58 | 2 |
| Wong J, 2020 | Brunei, NR | 138 | 16 | NR | NR | 2, 3 |
| Almazeedi S, 2020 | Kuwait, NR | 1,096 | 473 | NR | NR | 3 |
| Wi YM, 2020 | South Korea, Gyeongsangnam-do province | 111 | 7 | NR | NR | 3 |
| Kutsuna S, 2020 | Japan, Tokyo | 11 | 3 | 1 F, 2 M | NR | 2, 3 |
| Eythorsson E, 2020 | Iceland, NR | 178 | 25 | NR | NR | 2, 4 |
| Chamie G, 2020 | United States of America, San Francisco | 81 | 23 | NR | NR | 2, 4 |
| AbdulRahman A, 2020 | Bahrain, NR | 6 | 3 | 0 F, 3 M | 25 | 2, 3 |
| Edelstein M, 2020 | United Kingdom, London | 20 | 4 | NR | NR | 3, 4 |
| Al-Qahtani M, 2020 | Bahrain, NR | 188 | 116 | NR | NR | 2, 3, 4 |
| Cao S, 2020 | China, Wuhan | 300 | 300 | 168 F, 132 M | NR | 1, 3 |
| Migisha R, 2020 | Uganda, NR | 54 | 20 | NR | NR | 2, 4 |
| Meyers KJ, 2021 | United States of America, Indianapolis | 86 | 67 | NR | NR | 2, 4 |
| Rauch JN, 2021 | United States of America, California | 6 | 2 | NR | NR | 2, 4 |
| Theuring S, 2021 | Germany, Berlin | 10 | 2 | NR | NR | 2, 4 |
| Theuring S, 2021 [cluster 2] | Germany, Berlin | 14 | 0 | NR | NR | 2, 4 |
| setting: Screening: institutional setting | | | | | | |
| London V, 2020 | United States of America, New York City | 68 | 22 | 22 F, 0 M | 30.5 IQR 24.5-34.8 | 2, 4 |
| Andrikopoulou M, 2020 | United States of America, New York | 158 | 46 | 46 F, 0 M | NR | 2 |
| Bogani G, 2020 | Italy, Lombardy | 19 | 10 | 10 F, 0 M | NR | 3 |
| Kirshblum SC, 2020 | United States of America, New Jersey | 12 | 2 | NR | NR | 2, 4 |
| Smith E, 2020 | United Kingdom, Norfolk | 103 | 42 | NR | NR | 2, 4 |
| Tanacan A, 2020 | Turkey, Ankara | 3 | 0 | NR | NR | 3 |
| Starling A, 2020 | United Kingdom, Essex | 31 | 29 | NR | NR | 2, 4 |
| Marossy A, 2020 | United Kingdom, London | 67 | 46 | NR | NR | 2, 3 |
| Viñuela MC, 2020 | Spain, Madrid | 8 | 8 | 8 F, 0 M | 32 | 3 |
| Bender WR, 2020 | United States of America, Philadelphia, PA | 8 | 6 | 6 F, 0 M | NR | 2, 4 |
| Shi SM, 2020 | United States of America, Boston, MA | 146 | 21 | NR | NR | 2, 4 |
| Berghoff AS, 2020 | Austria, Vienna | 4 | 2 | NR | 53 IQR 43-63 | 1, 2, 3 |
| White EM, 2020 | United States of America, NR | 5,403 | 2,194 | NR | NR | 2, 4 |
| Aslam A, 2020 | United States of America, New York | 65 | 38 | NR | NR | 2, 4 |
| Adhikari EH, 2020 | United States of America, Texas | 252 | 98 | 98 F, 0 M | NR | 2, 4 |
| Ghinai I, 2020 | United States of America, Chicago | 406 | 293 | NR | NR | 2, 4 |
| Wadhwa A, 2020 | United States of America, Chicago | 17 | 6 | NR | NR | 2 |
| Balestrini S, 2020 | United Kingdom, London | 17 | 11 | NR | NR | 3 |
| Hcini N, 2020 | French Guyana, West French Guiana territory | 137 | 87 | 87 F, 0 M | NR | 2, 4 |
| van Buul LW, 2020 | Netherlands, NR | 16 | 3 | NR | NR | 2, 4 |
| Green R, 2021 | United Kingdom, Liverpool | 22 | 22 | 15 F, 7 M | 80 IQR 19-106 | 2, 4 |
| Varnell C, 2021 | United States of America, NR | 10 | 5 | NR | NR | 2 |
| Pizarro-Sánchez MS, 2021 | Spain, Madrid | 38 | 5 | 2 F, 3 M | NR | 2, 4 |
| van Buul LW, 2020 [cluster 2] | Netherlands, NR | 9 | 0 | NR | NR | 2, 4 |
| setting: Screening: occupational | | | | | | |
| Rivett L, 2020 | United Kingdom, Cambridge | 30 | 5 | NR | NR | 2 |
| Treibel TA, 2020 | United Kingdom, London | 44 | 12 | NR | NR | 2, 4 |
| Han X, 2020 | China, Wuhan | 17 | 17 | 8 F, 9 M | 30 IQR 27-30 | 2 |
| Lombardi A, 2020 | Italy, Lombardy | 139 | 17 | NR | NR | 1, 2, 3 |
| Cariani L, 2020 | Italy, Milan | 182 | 32 | NR | NR | 2, 3 |
| Stock AD, 2020 | United States of America, New York City | 19 | 6 | NR | NR | 1, 2 |
| Malagón-Rojas J, 2020 | Colombia, Bogota | 35 | 11 | NR | NR | 2, 4 |
| Letizia AG, 2020 | United States of America, South Carolina | 51 | 46 | NR | NR | 1, 2 |
| Mahajan NN, 2020 | India, Mumbai | 467 | 58 | NR | NR | 3 |
| Alshahrani MS, 2020 | Saudi Arabia, Alkhobar | 18 | 12 | NR | NR | 3 |
| Hogan CA, 2021 | United States of America, California | 38 | 20 | 13 F, 7 M | 41 IQR 32.5-47 | 2, 4 |
| Ferreira VH, 2021 | Canada, Toronto | 9 | 5 | 5 F, 0 M | 33 IQR 4.75 | 2, 4 |
| Tan-Loh J, 2021 | Malaysia, Teluk Intan | 46 | 6 | NR | NR | 2, 3, 4 |
| aFollow-up according to protocol (1: 14 days after last possible exposure; 2: 7 days after diagnosis; 3: until negative RT-PCR result; 4:>7 days after diagnosis). NR = not reported. | | | | | | |